A range of groundbreaking and potentially practice-changing gastrointestinal cancer studies were presented or published in 2024.

1 day ago · The Food and Drug Administration (FDA) has approved 2 additional vial sizes of Niktimvo ™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size. Niktimvo, a colony stimulating factor-1 receptor-blocking antibody, was approved in 2024 for the treatment of chronic graft-vs-host disease (GVHD) after failure of at least 2 prior lines of systemic therapy in adult and ...

1 day ago · Improved survival seen with perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel versus preoperative chemoradiotherapy. HealthDay News — For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin ...

10 hours ago · Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

1 day ago · Patients with cryptogenic cirrhosis and definite celiac disease experienced significant clinical benefits when following a gluten-free diet.

Dec 27, 2024 · This page includes links to articles highlighting the top gastrointestinal cancer research published on Cancer Therapy Advisor in 2024.

Sep 8, 2023 · Two clinicians weigh in on the link between semaglutide and gastroparesis and how to help patients manage symptoms.

Jan 13, 2025 · Nivolumab alone and in combination therapy improved overall and progression-free survival rates in patients with advanced gastric and gastroesophageal junction cancer; however, the risk for adverse events is high.

Sep 1, 2023 · Recent reports of severe semaglutide adverse events, such as gastroparesis, have raised concerns about the drug used for weight loss and type 2 diabetes.

While HIPAA rules protect health information of patients in hospitals and for physician visits, generally they do not protect the privacy or security of a patient’s health and wellness information when it is created accessed through or stored on personal cell …